Presently, the FDA has not approved a single antiviral drug for COVID-19, and there is an urgent need to develop effective therapeutic strategies that can suppress SARS-CoV-2 infections. Many approaches have been researched, including emerging exosome-based therapies. The interplay between exosomes and viruses could be potentially exploited for antiviral drug and vaccine development. Exosomes are produced by virus-infected cells and play integral roles in mediating communication between uninfected and infected cells.
Coronavirus modulates the production and composition of exosomes and can exploit exosome secretion, formation, and release pathways to promote infection, transmission, and intercellular spread. The possibility of using exosomes for therapeutic benefits thus throws up lucrative opportunities for entities in this space; many companies are participating in clinical trials and driving the market for research products and services.
Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=224782498
[191 Pages Report] The global exosome research market is projected to reach USD 661 million by 2026 from USD 144 million in 2021, at a CAGR of 35.6% during the forecast period. The growth of this market is driven by factors such as the rising funding for life sciences research, the high global prevalence of cancer, and the increasing interest in exosome-based procedures.
Trends suggest that the top pharma companies are increasing their R&D efficiencies through heavy R&D investments to see returns in the longer term and through collaborative R&D efforts. According to the EvaluatePharma report, worldwide pharmaceutical R&D spending was valued at USD 136 billion in 2012; this increased to USD 186 billion in 2019.
As a result of the COVID-19 outbreak, the global pharma R&D growth rate dropped to 0.3% in 2020. As per the report, this R&D spend is expected to grow steadily between 2019 and 2026 at a CAGR of 3.2% to reach USD 232.5 billion, slower than the historical CAGR of 4.6% between 2012 and 2019.
In recent years, partnering earlier in the drug development process as part of an effort to create efficiencies is a growing trend. Companies are increasingly outsourcing specialized testing services such as Liquid Chromatography-Mass Spectrometry (LC/MS), RNA sequencing, gene expression analysis, wet chemistry analysis of compendia raw materials, trace metal analysis with Inductively Coupled Mass Spectrometry (ICP-MS), and various others much earlier in the API process development cycle.
Based on application, the exosome research products market is segmented into biomarkers, vaccine development, tissue regeneration, and other applications. The biomarkers segment generated the highest revenue in the exosome research market in 2020.
Key Market Players
Thermo Fisher Scientific (US), Bio-Techne (US), Lonza (Switzerland), QIAGEN (Germany), Miltenyi Biotec (US), are the prominent players operating in the exosome research market.